Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Defence Therapeutics Inc.
  6. News
  7. Summary
    DTC   CA24463V1013

DEFENCE THERAPEUTICS INC.

(DTC)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Defence Therapeutics Inc. Reports Successful Completion of its COVID-19 Vaccine AccuVAC-PT001 Toxicology Studies in Rabbits

11/03/2021 | 02:30am EST

Defence Therapeutics Inc. announced the successful completion of its protein-based COVID vaccine (AccuVAC-PT001) toxicology studies in non-rodent rabbit model. The AccuVAC-PT001 vaccine is an injectable vaccine capable of inducing a powerful and sustainable antibody response in both rodent and non-rodent models. The vaccine proprietary recipe consists of chemically modifying the COVID Spike protein with the AccumTM moiety. Once delivered in animals, the protein accumulates very efficiently in target antigen presenting cells leading to extremely high antibody titers. Extensive analyses conducted on vaccinated rabbits showed no effects induced by the vaccine on animal behaviour, food intake, body weight, skin at injected sites and liver enzymatic function amongst other investigated organs. Defence is currently working on two different protein-based vaccine candidates.


ę S&P Capital IQ 2021
All news about DEFENCE THERAPEUTICS INC.
01/26DEFENCE THERAPEUTICS INC. : Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) acti..
EQ
01/26Defence Therapeutics Inc. Announces the Development of AccuVAC-PT009
CI
01/10Defence therapeutics achieves a major milestone and begins ind-enabling testing of its ..
EQ
01/10Defence Therapeutics Inc. Begins Ind-Enabling Testing of its Accutox Lead Compound Agai..
CI
2021Defence Therapeutics Inc. Accum(TM) Boosts by 9-Fold the Delivery Effectiveness of CRIS..
CI
2021Defence therapeutics accumtm boosts by 9-fold the delivery effectiveness of the crispr/..
EQ
2021Defence therapeutics vaccines and program development
EQ
2021Defence therapeutics cancer vaccine accuvac-d001 manufacturing targets melanoma and bre..
EQ
2021Defence therapeutics appoints dr. riam shammaa to its board of directors
EQ
2021Defence Therapeutics Inc. Appoints Riam Shammaa to its Board of Directors
CI
More news
Financials
Sales 2021 - - -
Net income 2021 -2,86 M -2,24 M -2,24 M
Net cash 2021 5,45 M 4,27 M 4,27 M
P/E ratio 2021 -65,6x
Yield 2021 -
Capitalization 186 M 146 M 146 M
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees -
Free-Float -
Chart DEFENCE THERAPEUTICS INC.
Duration : Period :
Defence Therapeutics Inc. Technical Analysis Chart | DTC | CA24463V1013 | MarketScreener
Income Statement Evolution
Managers and Directors
SÚbastien Plouffe President, Chief Executive Officer & Director
P. Joseph Meagher Chief Financial Officer & Director
Raimar L÷benberg Chairman
Simon Beaudoin Chief Technology & Science Officer
Moutih Rafei Director & VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
DEFENCE THERAPEUTICS INC.0.00%146
MODERNA, INC.-37.21%64 657
LONZA GROUP AG-17.41%50 233
IQVIA HOLDINGS INC.-15.35%45 624
SEAGEN INC.-17.45%23 336
ICON PUBLIC LIMITED COMPANY-15.10%21 404